Publications

  1. Ring, P, Keil, J, Muthuraman, M, Wolff, S, Bergmann, TO, Probst, C et al.. Oscillatory brain activity associated with skin conductance responses in the context of risk. J Neurophysiol. 2021;126 (3):924-933. doi: 10.1152/jn.00014.2021. PubMed PMID:34346697 .
  2. Pfeil, J, Hoenig, MC, Doering, E, van Eimeren, T, Drzezga, A, Bischof, GN et al.. Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease. Neurobiol Aging. 2021;106 :119-129. doi: 10.1016/j.neurobiolaging.2021.06.014. PubMed PMID:34284259 .
  3. Ring, P, Probst, CC, Neyse, L, Wolff, S, Kaernbach, C, van Eimeren, T et al.. Discounting Behavior in Problem Gambling. J Gambl Stud. 2021; :. doi: 10.1007/s10899-021-10054-x. PubMed PMID:34268669 .
  4. Jergas, H, Grindegård, L, Schultze, T, Thanarajah, SE, Kalbe, E, van Eimeren, T et al.. The impact of subthalamic deep brain stimulation on belief revision and social validation. Parkinsonism Relat Disord. 2021;89 :84-86. doi: 10.1016/j.parkreldis.2021.06.020. PubMed PMID:34256332 .
  5. Song, M, Beyer, L, Kaiser, L, Barthel, H, van Eimeren, T, Marek, K et al.. Binding characteristics of [F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET. J Cereb Blood Flow Metab. 2021; :271678X211018904. doi: 10.1177/0271678X211018904. PubMed PMID:34044665 .
  6. Song, M, Scheifele, M, Barthel, H, van Eimeren, T, Beyer, L, Marek, K et al.. Feasibility of short imaging protocols for [F]PI-2620 tau-PET in progressive supranuclear palsy. Eur J Nucl Med Mol Imaging. 2021; :. doi: 10.1007/s00259-021-05391-3. PubMed PMID:34021393 .
  7. Schedlich-Teufer, C, Jost, ST, Krack, P, Witt, K, Weintraub, D, Baldermann, JC et al.. Assessment of Affective-Behavioral States in Parkinson's Disease Patients: Towards a New Screening Tool. J Parkinsons Dis. 2021;11 (3):1417-1430. doi: 10.3233/JPD-202375. PubMed PMID:33967055 .
  8. Palleis, C, Brendel, M, Finze, A, Weidinger, E, Bötzel, K, Danek, A et al.. Cortical [ F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. Mov Disord. 2021;36 (9):2104-2115. doi: 10.1002/mds.28624. PubMed PMID:33951244 .
  9. Bischof, GN, Bartenstein, P, Barthel, H, van Berckel, B, Doré, V, van Eimeren, T et al.. Toward a Universal Readout for F-Labeled Amyloid Tracers: The CAPTAINs Study. J Nucl Med. 2021;62 (7):999-1005. doi: 10.2967/jnumed.120.250290. PubMed PMID:33712532 .
  10. Boccardi, M, Dodich, A, Albanese, E, Gayet-Ageron, A, Festari, C, Ashton, NJ et al.. The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. Eur J Nucl Med Mol Imaging. 2021;48 (7):2070-2085. doi: 10.1007/s00259-020-05120-2. PubMed PMID:33688996 PubMed Central PMC8175304.
  11. Schaible, F, Maier, F, Buchwitz, TM, Schwartz, F, Hoock, M, Schönau, E et al.. Effects of Lee Silverman Voice Treatment BIG and conventional physiotherapy on non-motor and motor symptoms in Parkinson's disease: a randomized controlled study comparing three exercise models. Ther Adv Neurol Disord. 2021;14 :1756286420986744. doi: 10.1177/1756286420986744. PubMed PMID:33680093 PubMed Central PMC7897809.
  12. Ruppert, MC, Greuel, A, Freigang, J, Tahmasian, M, Maier, F, Hammes, J et al.. The default mode network and cognition in Parkinson's disease: A multimodal resting-state network approach. Hum Brain Mapp. 2021;42 (8):2623-2641. doi: 10.1002/hbm.25393. PubMed PMID:33638213 PubMed Central PMC8090788.
  13. Bischof, GN, Dodich, A, Boccardi, M, van Eimeren, T, Festari, C, Barthel, H et al.. Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021;48 (7):2110-2120. doi: 10.1007/s00259-020-05156-4. PubMed PMID:33590274 PubMed Central PMC8175320.
  14. Seemiller, J, Bischof, GN, Hoenig, MC, Tahmasian, M, van Eimeren, T, Drzezga, A et al.. Indication of retrograde tau spreading along Braak stages and functional connectivity pathways. Eur J Nucl Med Mol Imaging. 2021;48 (7):2272-2282. doi: 10.1007/s00259-020-05183-1. PubMed PMID:33462630 PubMed Central PMC8178161.
  15. Ophey, A, Rehberg, S, Giehl, K, Eggers, C, Reker, P, van Eimeren, T et al.. Predicting Working Memory Training Responsiveness in Parkinson's Disease: Both "System Hardware" and Room for Improvement Are Needed. Neurorehabil Neural Repair. 2021;35 (2):117-130. doi: 10.1177/1545968320981956. PubMed PMID:33410387 .
  16. Weller, A, Bischof, GN, Schlüter, P, Richter, N, Dronse, J, Onur, O et al.. Finding New Communities: A Principle of Neuronal Network Reorganization in Alzheimer's Disease. Brain Connect. 2021;11 (3):225-238. doi: 10.1089/brain.2020.0889. PubMed PMID:33356820 .
  17. Hoenig, MC, Willscheid, N, Bischof, GN, van Eimeren, T, Drzezga, A, Alzheimer’s Disease Neuroimaging Initiative et al.. Assessment of Tau Tangles and Amyloid-β Plaques Among Super Agers Using PET Imaging. JAMA Netw Open. 2020;3 (12):e2028337. doi: 10.1001/jamanetworkopen.2020.28337. PubMed PMID:33306113 PubMed Central PMC7733158.
  18. Brendel, M, Barthel, H, van Eimeren, T, Marek, K, Beyer, L, Song, M et al.. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol. 2020;77 (11):1408-1419. doi: 10.1001/jamaneurol.2020.2526. PubMed PMID:33165511 PubMed Central PMC7341407.
  19. Richter, N, Bischof, GN, Dronse, J, Nellessen, N, Neumaier, B, Langen, KJ et al.. Entorhinal Tau Predicts Hippocampal Activation and Memory Deficits in Alzheimer's Disease. J Alzheimers Dis. 2020;78 (4):1601-1614. doi: 10.3233/JAD-200835. PubMed PMID:33164934 .
  20. van Eimeren, T, Claßen, J, Drzezga, A, Eggers, C, Hilker-Roggendorf, R, Klucken, J et al.. [Recommendation for the differentiated use of nuclear medical diagnostic for parkinsonian syndromes]. Fortschr Neurol Psychiatr. 2020;88 (9):609-619. doi: 10.1055/a-1207-0515. PubMed PMID:32957144 .
  21. Giehl, K, Ophey, A, Hammes, J, Rehberg, S, Lichtenstein, T, Reker, P et al.. Working memory training increases neural efficiency in Parkinson's disease: a randomized controlled trial. Brain Commun. 2020;2 (2):fcaa115. doi: 10.1093/braincomms/fcaa115. PubMed PMID:32954349 PubMed Central PMC7472906.
  22. Hammes, J, Bischof, GN, Bohn, KP, Onur, Ö, Schneider, A, Fliessbach, K et al.. One-Stop Shop: F-Flortaucipir PET Differentiates Amyloid-Positive and -Negative Forms of Neurodegenerative Diseases. J Nucl Med. 2021;62 (2):240-246. doi: 10.2967/jnumed.120.244061. PubMed PMID:32620704 .
  23. van Eimeren, T. Central autonomic dysfunction in multiple system atrophy: can we measure it with MRI?. Clin Auton Res. 2020;30 (3):185-187. doi: 10.1007/s10286-020-00695-0. PubMed PMID:32418031 PubMed Central PMC7250800.
  24. Beyer, L, Nitschmann, A, Barthel, H, van Eimeren, T, Unterrainer, M, Sauerbeck, J et al.. Early-phase [F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. Eur J Nucl Med Mol Imaging. 2020;47 (12):2911-2922. doi: 10.1007/s00259-020-04788-w. PubMed PMID:32318783 PubMed Central PMC7567714.
  25. Ophey, A, Giehl, K, Rehberg, S, Eggers, C, Reker, P, van Eimeren, T et al.. Effects of working memory training in patients with Parkinson's disease without cognitive impairment: A randomized controlled trial. Parkinsonism Relat Disord. 2020;72 :13-22. doi: 10.1016/j.parkreldis.2020.02.002. PubMed PMID:32078917 .
  26. Ruppert, MC, Greuel, A, Tahmasian, M, Schwartz, F, Stürmer, S, Maier, F et al.. Network degeneration in Parkinson's disease: multimodal imaging of nigro-striato-cortical dysfunction. Brain. 2020;143 (3):944-959. doi: 10.1093/brain/awaa019. PubMed PMID:32057084 .
  27. Giehl, K, Ophey, A, Reker, P, Rehberg, S, Hammes, J, Barbe, MT et al.. Effects of Home-Based Working Memory Training on Visuo-Spatial Working Memory in Parkinson's Disease: A Randomized Controlled Trial. J Cent Nerv Syst Dis. 2020;12 :1179573519899469. doi: 10.1177/1179573519899469. PubMed PMID:32002011 PubMed Central PMC6966247.
  28. van Eimeren, T, Drzezga, A. From molecules to system failure: translational frontiers of multimodal imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2019;46 (13):2816-2818. doi: 10.1007/s00259-019-04562-7. PubMed PMID:31667539 .
  29. Dietlein, F, Kobe, C, Hohberg, M, Zlatopolskiy, BD, Krapf, P, Endepols, H et al.. Intraindividual Comparison of F-PSMA-1007 with Renally Excreted PSMA Ligands for PSMA PET Imaging in Patients with Relapsed Prostate Cancer. J Nucl Med. 2020;61 (5):729-734. doi: 10.2967/jnumed.119.234898. PubMed PMID:31628219 .
  30. Respondek, G, Grimm, MJ, Piot, I, Arzberger, T, Compta, Y, Englund, E et al.. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. Mov Disord. 2020;35 (1):171-176. doi: 10.1002/mds.27872. PubMed PMID:31571273 PubMed Central PMC7993399.
  31. Baldermann, JC, Bohn, KP, Hammes, J, Schüller, CB, Visser-Vandewalle, V, Drzezga, A et al.. Local and Global Changes in Brain Metabolism during Deep Brain Stimulation for Obsessive-Compulsive Disorder. Brain Sci. 2019;9 (9):. doi: 10.3390/brainsci9090220. PubMed PMID:31480355 PubMed Central PMC6770477.
  32. Hohberg, M, Kobe, C, Krapf, P, Täger, P, Hammes, J, Dietlein, F et al.. Biodistribution and radiation dosimetry of [F]-JK-PSMA-7 as a novel prostate-specific membrane antigen-specific ligand for PET/CT imaging of prostate cancer. EJNMMI Res. 2019;9 (1):66. doi: 10.1186/s13550-019-0540-7. PubMed PMID:31346821 PubMed Central PMC6658635.
  33. Sehlin, D, Syvänen, S, MINC faculty. Engineered antibodies: new possibilities for brain PET?. Eur J Nucl Med Mol Imaging. 2019;46 (13):2848-2858. doi: 10.1007/s00259-019-04426-0. PubMed PMID:31342134 PubMed Central PMC6879437.
  34. Dietlein, F, Hohberg, M, Kobe, C, Zlatopolskiy, BD, Krapf, P, Endepols, H et al.. An F-Labeled PSMA Ligand for PET/CT of Prostate Cancer: First-in-Humans Observational Study and Clinical Experience with F-JK-PSMA-7 During the First Year of Application. J Nucl Med. 2020;61 (2):202-209. doi: 10.2967/jnumed.119.229542. PubMed PMID:31324713 .
  35. Bischof, GN, Ewers, M, Franzmeier, N, Grothe, MJ, Hoenig, M, Kocagoncu, E et al.. Connectomics and molecular imaging in neurodegeneration. Eur J Nucl Med Mol Imaging. 2019;46 (13):2819-2830. doi: 10.1007/s00259-019-04394-5. PubMed PMID:31292699 .
  36. Riederer, P, Berg, D, Casadei, N, Cheng, F, Classen, J, Dresel, C et al.. α-Synuclein in Parkinson's disease: causal or bystander?. J Neural Transm (Vienna). 2019;126 (7):815-840. doi: 10.1007/s00702-019-02025-9. PubMed PMID:31240402 .
  37. Hoenig, MC, Bischof, GN, Onur, ÖA, Kukolja, J, Jessen, F, Fliessbach, K et al.. Level of education mitigates the impact of tau pathology on neuronal function. Eur J Nucl Med Mol Imaging. 2019;46 (9):1787-1795. doi: 10.1007/s00259-019-04342-3. PubMed PMID:31183635 .
  38. Trampenau, L, Kuhtz-Buschbeck, JP, van Eimeren, T. Parkinsonian patients do not utilize probabilistic advance information in a grip-lift task. Parkinsonism Relat Disord. 2019;65 :67-72. doi: 10.1016/j.parkreldis.2019.05.015. PubMed PMID:31105014 .
  39. van Eimeren, T, Antonini, A, Berg, D, Bohnen, N, Ceravolo, R, Drzezga, A et al.. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. Alzheimers Dement (Amst). 2019;11 :301-309. doi: 10.1016/j.dadm.2019.01.011. PubMed PMID:30984816 PubMed Central PMC6446052.
  40. Yilmaz, R, Hopfner, F, van Eimeren, T, Berg, D. Biomarkers of Parkinson's disease: 20 years later. J Neural Transm (Vienna). 2019;126 (7):803-813. doi: 10.1007/s00702-019-02001-3. PubMed PMID:30949837 .
  41. Grimm, MJ, Respondek, G, Stamelou, M, Arzberger, T, Ferguson, L, Gelpi, E et al.. How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. Mov Disord. 2019;34 (8):1228-1232. doi: 10.1002/mds.27666. PubMed PMID:30884545 PubMed Central PMC6699888.
  42. Giehl, K, Tahmasian, M, Eickhoff, SB, van Eimeren, T. Imaging executive functions in Parkinson's disease: An activation likelihood estimation meta-analysis. Parkinsonism Relat Disord. 2019;63 :137-142. doi: 10.1016/j.parkreldis.2019.02.015. PubMed PMID:30833230 .
  43. Hammes, J, Theis, H, Giehl, K, Hoenig, MC, Greuel, A, Tittgemeyer, M et al.. Dopamine metabolism of the nucleus accumbens and fronto-striatal connectivity modulate impulse control. Brain. 2019;142 (3):733-743. doi: 10.1093/brain/awz007. PubMed PMID:30753324 .
  44. Strafella, AP, Bohnen, NI, Pavese, N, Vaillancourt, DE, van Eimeren, T, Politis, M et al.. Imaging Markers of Progression in Parkinson's Disease. Mov Disord Clin Pract. ;5 (6):586-596. doi: 10.1002/mdc3.12673. PubMed PMID:30637278 PubMed Central PMC6277366.
  45. Hammes, J, Hohberg, M, Täger, P, Wild, M, Zlatopolskiy, B, Krapf, P et al.. Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT. PLoS One. 2018;13 (12):e0209613. doi: 10.1371/journal.pone.0209613. PubMed PMID:30571794 PubMed Central PMC6301686.
  46. Hammes, J, van Heek, L, Hohberg, M, Reifegerst, M, Stockter, S, Dietlein, M et al.. Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases. EJNMMI Phys. 2018;5 (1):32. doi: 10.1186/s40658-018-0231-x. PubMed PMID:30539323 PubMed Central PMC6289932.
  47. Baumann, A, Nebel, A, Granert, O, Giehl, K, Wolff, S, Schmidt, W et al.. Neural Correlates of Hypokinetic Dysarthria and Mechanisms of Effective Voice Treatment in Parkinson Disease. Neurorehabil Neural Repair. 2018;32 (12):1055-1066. doi: 10.1177/1545968318812726. PubMed PMID:30444176 .
  48. Hammes, J, Drzezga, A, van Eimeren, T. The Role of Tau Imaging in Parkinsonian Disorders. Curr Neurol Neurosci Rep. 2018;18 (12):86. doi: 10.1007/s11910-018-0898-3. PubMed PMID:30293094 .
  49. Dodel, R, Koschel, J, Lorenzl, S, Levin, J, van Eimeren, T, Höglinger, G et al.. [Dementia with Lewy bodies]. Fortschr Neurol Psychiatr. 2018;86 (S 01):S43-S47. doi: 10.1055/a-0696-6249. PubMed PMID:30241100 .
  50. Kovacs, GG, Respondek, G, van Eimeren, T, Höller, E, Levin, J, Müller, U et al.. [Tauopathies : From molecule to therapy]. Nervenarzt. 2018;89 (10):1083-1094. doi: 10.1007/s00115-018-0584-3. PubMed PMID:30120488 .
  51. Hohberg, M, Kobe, C, Täger, P, Hammes, J, Schmidt, M, Dietlein, F et al.. Combined Early and Late [Ga]PSMA-HBED-CC PET Scans Improve Lesion Detectability in Biochemical Recurrence of Prostate Cancer with Low PSA Levels. Mol Imaging Biol. 2019;21 (3):558-566. doi: 10.1007/s11307-018-1263-2. PubMed PMID:30105521 .
  52. Chong, TT, Apps, MAJ, Giehl, K, Hall, S, Clifton, CH, Husain, M et al.. Computational modelling reveals distinct patterns of cognitive and physical motivation in elite athletes. Sci Rep. 2018;8 (1):11888. doi: 10.1038/s41598-018-30220-3. PubMed PMID:30089782 PubMed Central PMC6082862.
  53. Ring, P, Probst, CC, Neyse, L, Wolff, S, Kaernbach, C, van Eimeren, T et al.. It's all about gains: Risk preferences in problem gambling. J Exp Psychol Gen. 2018;147 (8):1241-1255. doi: 10.1037/xge0000418. PubMed PMID:29878809 .
  54. Schweyer, K, Busche, MA, Hammes, J, Zwergal, A, Buhmann, C, van Eimeren, T et al.. Pearls & Oy-sters: Ocular motor apraxia as essential differential diagnosis to supranuclear gaze palsy: Eyes up. Neurology. 2018;90 (10):482-485. doi: 10.1212/WNL.0000000000005069. PubMed PMID:29507134 .
  55. Schwartz, F, Tahmasian, M, Maier, F, Rochhausen, L, Schnorrenberg, KL, Samea, F et al.. Overlapping and distinct neural metabolic patterns related to impulsivity and hypomania in Parkinson's disease. Brain Imaging Behav. 2019;13 (1):241-254. doi: 10.1007/s11682-017-9812-x. PubMed PMID:29322397 .
  56. Hoenig, MC, Bischof, GN, Seemiller, J, Hammes, J, Kukolja, J, Onur, ÖA et al.. Networks of tau distribution in Alzheimer's disease. Brain. 2018;141 (2):568-581. doi: 10.1093/brain/awx353. PubMed PMID:29315361 .
  57. Hammes, J, Täger, P, Drzezga, A. EBONI: A Tool for Automated Quantification of Bone Metastasis Load in PSMA PET/CT. J Nucl Med. 2018;59 (7):1070-1075. doi: 10.2967/jnumed.117.203265. PubMed PMID:29242401 .
  58. Hammes, J, Leuwer, I, Bischof, GN, Drzezga, A, van Eimeren, T. Multimodal correlation of dynamic [F]-AV-1451 perfusion PET and neuronal hypometabolism in [F]-FDG PET. Eur J Nucl Med Mol Imaging. 2017;44 (13):2249-2256. doi: 10.1007/s00259-017-3840-z. PubMed PMID:29026951 .
  59. Hammes, J, Kobe, C, Hilgenberg, U, Lieb, WE, Drzezga, A. Orbital Hemangiopericytoma in 68Ga-Prostate-Specific Membrane Antigen-HBED-CC PET/CT. Clin Nucl Med. 2017;42 (10):812-814. doi: 10.1097/RLU.0000000000001791. PubMed PMID:28806257 .
  60. Bischof, GN, Endepols, H, van Eimeren, T, Drzezga, A. Tau-imaging in neurodegeneration. Methods. 2017;130 :114-123. doi: 10.1016/j.ymeth.2017.08.003. PubMed PMID:28790016 .
  61. Hoenig, MC, Bischof, GN, Hammes, J, Faber, J, Fliessbach, K, van Eimeren, T et al.. Tau pathology and cognitive reserve in Alzheimer's disease. Neurobiol Aging. 2017;57 :1-7. doi: 10.1016/j.neurobiolaging.2017.05.004. PubMed PMID:28577411 .
  62. Kreutzer, C, Peters, S, Schulte, DM, Fangmann, D, Türk, K, Wolff, S et al.. Hypothalamic Inflammation in Human Obesity Is Mediated by Environmental and Genetic Factors. Diabetes. 2017;66 (9):2407-2415. doi: 10.2337/db17-0067. PubMed PMID:28576837 .
  63. Farrell, ME, Kennedy, KM, Rodrigue, KM, Wig, G, Bischof, GN, Rieck, JR et al.. Association of Longitudinal Cognitive Decline With Amyloid Burden in Middle-aged and Older Adults: Evidence for a Dose-Response Relationship. JAMA Neurol. 2017;74 (7):830-838. doi: 10.1001/jamaneurol.2017.0892. PubMed PMID:28558099 PubMed Central PMC5710531.
  64. Respondek, G, Kurz, C, Arzberger, T, Compta, Y, Englund, E, Ferguson, LW et al.. Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Mov Disord. 2017;32 (7):995-1005. doi: 10.1002/mds.27034. PubMed PMID:28500752 PubMed Central PMC5543934.
  65. Whitwell, JL, Höglinger, GU, Antonini, A, Bordelon, Y, Boxer, AL, Colosimo, C et al.. Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be?. Mov Disord. 2017;32 (7):955-971. doi: 10.1002/mds.27038. PubMed PMID:28500751 PubMed Central PMC5511762.
  66. van Eimeren, T, Bischof, GN, Drzezga, A. Is Tau Imaging More Than Just Upside-Down F-FDG Imaging?. J Nucl Med. 2017;58 (9):1357-1359. doi: 10.2967/jnumed.117.190082. PubMed PMID:28490468 .
  67. Tahmasian, M, Eickhoff, SB, Giehl, K, Schwartz, F, Herz, DM, Drzezga, A et al.. Resting-state functional reorganization in Parkinson's disease: An activation likelihood estimation meta-analysis. Cortex. 2017;92 :119-138. doi: 10.1016/j.cortex.2017.03.016. PubMed PMID:28467917 PubMed Central PMC8005854.
  68. Höglinger, GU, Respondek, G, Stamelou, M, Kurz, C, Josephs, KA, Lang, AE et al.. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov Disord. 2017;32 (6):853-864. doi: 10.1002/mds.26987. PubMed PMID:28467028 PubMed Central PMC5516529.
  69. Chong, TT, Apps, M, Giehl, K, Sillence, A, Grima, LL, Husain, M et al.. Neurocomputational mechanisms underlying subjective valuation of effort costs. PLoS Biol. 2017;15 (2):e1002598. doi: 10.1371/journal.pbio.1002598. PubMed PMID:28234892 PubMed Central PMC5325181.
  70. Strafella, AP, Bohnen, NI, Perlmutter, JS, Eidelberg, D, Pavese, N, Van Eimeren, T et al.. Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. Mov Disord. 2017;32 (2):181-192. doi: 10.1002/mds.26907. PubMed PMID:28150432 .
  71. Bischof, GN, Jessen, F, Fliessbach, K, Dronse, J, Hammes, J, Neumaier, B et al.. Impact of tau and amyloid burden on glucose metabolism in Alzheimer's disease. Ann Clin Transl Neurol. 2016;3 (12):934-939. doi: 10.1002/acn3.339. PubMed PMID:28097205 PubMed Central PMC5224823.
  72. Zokaei, N, Giehl, K, Sillence, A, Neville, MJ, Karpe, F, Nobre, AC et al.. Sex and APOE: A memory advantage in male APOE ε4 carriers in midlife. Cortex. 2017;88 :98-105. doi: 10.1016/j.cortex.2016.12.016. PubMed PMID:28086184 PubMed Central PMC5333781.
  73. Trampenau, L, van Eimeren, T, Kuhtz-Buschbeck, J. Processing of probabilistic information in weight perception and motor prediction. Atten Percept Psychophys. 2017;79 (2):404-414. doi: 10.3758/s13414-016-1266-5. PubMed PMID:28035624 .
  74. Bischof, GN, Rodrigue, KM, Kennedy, KM, Devous, MD Sr, Park, DC. Amyloid deposition in younger adults is linked to episodic memory performance. Neurology. 2016;87 (24):2562-2566. doi: 10.1212/WNL.0000000000003425. PubMed PMID:27837001 PubMed Central PMC5207002.
  75. Dronse, J, Fliessbach, K, Bischof, GN, von Reutern, B, Faber, J, Hammes, J et al.. In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease. J Alzheimers Dis. 2017;55 (2):465-471. doi: 10.3233/JAD-160316. PubMed PMID:27802224 .
  76. Hammes, J, Bischof, GN, Giehl, K, Faber, J, Drzezga, A, Klockgether, T et al.. Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. Mov Disord. 2017;32 (1):170-171. doi: 10.1002/mds.26727. PubMed PMID:27476874 .
  77. McDonough, IM, Bischof, GN, Kennedy, KM, Rodrigue, KM, Farrell, ME, Park, DC et al.. Discrepancies between fluid and crystallized ability in healthy adults: a behavioral marker of preclinical Alzheimer's disease. Neurobiol Aging. 2016;46 :68-75. doi: 10.1016/j.neurobiolaging.2016.06.011. PubMed PMID:27460151 PubMed Central PMC5018443.
  78. Rempe, T, Kuhlenbäumer, G, Krüger, S, Biskup, S, Matschke, J, Hagel, C et al.. Early-onset parkinsonism due to compound heterozygous POLG mutations. Parkinsonism Relat Disord. 2016;29 :135-7. doi: 10.1016/j.parkreldis.2016.04.020. PubMed PMID:27185166 .
  79. Achilles, EI, Maus, V, Fink, GR, Maintz, D, van Eimeren, T, Mpotsaris, A et al.. [Hemichorea with Contralateral High Signal Intensity Putaminal Lesion on T1-Weighted Images in Non-Ketotic Hyperglycemia]. Fortschr Neurol Psychiatr. 2016;84 (4):222-5. doi: 10.1055/s-0042-104347. PubMed PMID:27100847 .
  80. Lorenzen, A, Scholz-Hehn, D, Wiesner, CD, Wolff, S, Bergmann, TO, van Eimeren, T et al.. Chemosensory processing in children with attention-deficit/hyperactivity disorder. J Psychiatr Res. 2016;76 :121-7. doi: 10.1016/j.jpsychires.2016.02.007. PubMed PMID:26926800 .
  81. Zeuner, KE, Knutzen, A, Granert, O, Sablowsky, S, Götz, J, Wolff, S et al.. Altered brain activation in a reversal learning task unmasks adaptive changes in cognitive control in writer's cramp. Neuroimage Clin. 2016;10 :63-70. doi: 10.1016/j.nicl.2015.11.006. PubMed PMID:26702397 PubMed Central PMC4669532.
  82. Tahmasian, M, Rochhausen, L, Maier, F, Williamson, KL, Drzezga, A, Timmermann, L et al.. Impulsivity is Associated with Increased Metabolism in the Fronto-Insular Network in Parkinson's Disease. Front Behav Neurosci. 2015;9 :317. doi: 10.3389/fnbeh.2015.00317. PubMed PMID:26648853 PubMed Central PMC4664667.
  83. Rolinski, M, Zokaei, N, Baig, F, Giehl, K, Quinnell, T, Zaiwalla, Z et al.. Visual short-term memory deficits in REM sleep behaviour disorder mirror those in Parkinson's disease. Brain. 2016;139 (Pt 1):47-53. doi: 10.1093/brain/awv334. PubMed PMID:26582557 PubMed Central PMC4949392.
  84. McDonough, IM, Haber, S, Bischof, GN, Park, DC. The Synapse Project: Engagement in mentally challenging activities enhances neural efficiency. Restor Neurol Neurosci. 2015;33 (6):865-82. doi: 10.3233/RNN-150533. PubMed PMID:26484698 PubMed Central PMC4927925.
  85. Ponseti, J, Granert, O, Van Eimeren, T, Jansen, O, Wolff, S, Beier, K et al.. Assessing paedophilia based on the haemodynamic brain response to face images. World J Biol Psychiatry. 2016;17 (1):39-46. doi: 10.3109/15622975.2015.1083612. PubMed PMID:26452682 .
  86. Tahmasian, M, Bettray, LM, van Eimeren, T, Drzezga, A, Timmermann, L, Eickhoff, CR et al.. A systematic review on the applications of resting-state fMRI in Parkinson's disease: Does dopamine replacement therapy play a role?. Cortex. 2015;73 :80-105. doi: 10.1016/j.cortex.2015.08.005. PubMed PMID:26386442 .
  87. Granert, O, Drzezga, AE, Boecker, H, Perneczky, R, Kurz, A, Götz, J et al.. Metabolic Topology of Neurodegenerative Disorders: Influence of Cognitive and Motor Deficits. J Nucl Med. 2015;56 (12):1916-21. doi: 10.2967/jnumed.115.156067. PubMed PMID:26383147 .
  88. Probst, CC, Winter, LM, Möller, B, Weber, H, Weintraub, D, Witt, K et al.. Erratum to: Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the QUIP-rating scale in a German speaking sample. J Neurol. 2015;262 (9):2200. doi: 10.1007/s00415-015-7882-5. PubMed PMID:26338812 PubMed Central PMC4713996.
  89. Gerwinn, H, Pohl, A, Granert, O, van Eimeren, T, Wolff, S, Jansen, O et al.. The (in)consistency of changes in brain macrostructure in male paedophiles: A combined T1-weighted and diffusion tensor imaging study. J Psychiatr Res. 2015;68 :246-53. doi: 10.1016/j.jpsychires.2015.07.002. PubMed PMID:26228426 .
  90. Bischof, GN, Park, DC. Obesity and Aging: Consequences for Cognition, Brain Structure, and Brain Function. Psychosom Med. ;77 (6):697-709. doi: 10.1097/PSY.0000000000000212. PubMed PMID:26107577 PubMed Central PMC5648343.
  91. Paschen, L, Schmidt, N, Wolff, S, Cnyrim, C, van Eimeren, T, Zeuner, KE et al.. The olfactory bulb volume in patients with idiopathic Parkinson's disease. Eur J Neurol. 2015;22 (7):1068-73. doi: 10.1111/ene.12709. PubMed PMID:25912367 .
  92. Trampenau, L, Kuhtz-Buschbeck, JP, van Eimeren, T. Probabilistic information on object weight shapes force dynamics in a grip-lift task. Exp Brain Res. 2015;233 (6):1711-20. doi: 10.1007/s00221-015-4244-6. PubMed PMID:25761969 .
  93. Zeuner, KE, Knutzen, A, Granert, O, Götz, J, Wolff, S, Jansen, O et al.. Increased volume and impaired function: the role of the basal ganglia in writer's cramp. Brain Behav. 2015;5 (2):e00301. doi: 10.1002/brb3.301. PubMed PMID:25642386 PubMed Central PMC4309880.
  94. Kennedy, KM, Rodrigue, KM, Bischof, GN, Hebrank, AC, Reuter-Lorenz, PA, Park, DC et al.. Age trajectories of functional activation under conditions of low and high processing demands: an adult lifespan fMRI study of the aging brain. Neuroimage. 2015;104 :21-34. doi: 10.1016/j.neuroimage.2014.09.056. PubMed PMID:25284304 PubMed Central PMC4252495.
  95. Ponseti, J, Granert, O, van Eimeren, T, Jansen, O, Wolff, S, Beier, K et al.. Human face processing is tuned to sexual age preferences. Biol Lett. 2014;10 (5):20140200. doi: 10.1098/rsbl.2014.0200. PubMed PMID:24850896 PubMed Central PMC4046377.
  96. Probst, CC, Winter, LM, Möller, B, Weber, H, Weintraub, D, Witt, K et al.. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the QUIP-rating scale in a German speaking sample. J Neurol. 2014;261 (5):936-42. doi: 10.1007/s00415-014-7299-6. PubMed PMID:24609972 PubMed Central PMC4148320.
  97. van Eimeren, T. Is the Pill Questionnaire useless? Your move, MDS Task Force. J Neurol Neurosurg Psychiatry. 2014;85 (9):949. doi: 10.1136/jnnp-2013-307040. PubMed PMID:24357681 .
  98. Park, DC, Lodi-Smith, J, Drew, L, Haber, S, Hebrank, A, Bischof, GN et al.. The impact of sustained engagement on cognitive function in older adults: the Synapse Project. Psychol Sci. 2014;25 (1):103-12. doi: 10.1177/0956797613499592. PubMed PMID:24214244 PubMed Central PMC4154531.
  99. Goerlich-Dobre, KS, Probst, C, Winter, L, Witt, K, Deuschl, G, Möller, B et al.. Alexithymia-an independent risk factor for impulsive-compulsive disorders in Parkinson's disease. Mov Disord. 2014;29 (2):214-20. doi: 10.1002/mds.25679. PubMed PMID:24123483 .
  100. Probst, CC, van Eimeren, T. The functional anatomy of impulse control disorders. Curr Neurol Neurosci Rep. 2013;13 (10):386. doi: 10.1007/s11910-013-0386-8. PubMed PMID:23963609 PubMed Central PMC3779310.
  101. Hammes, J., Bischof, G.N. & Drzezga, A. Clin Transl Imaging (2017) 5: 465. https://doi.org/10.1007/s40336-017-0242-y
Search PubMed